Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx1 RVF Vaccine in Kenyan Adults
NCT06799234Phase 2Active, not recruiting
- Sponsor
- University of Oxford
- Start
- Jul 2025
- Primary completion
- Mar 2026
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised trial of ChAdOx1 RVF in Rift Valley fever (RVF) (3 arms), sponsored by University of Oxford. Primary endpoint: Rate of seroconversion for RVFV neutralizing antibodies at 28 days. Started Jul 2025; status: active, not recruiting.
02
Drugs
ChAdOx1 RVF
03
Conditions
Rift Valley fever (RVF)
Beyond the preview
Go deeper on NCT06799234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799234.